20
2016-2017 Cancer Program Annual Report
2016-2017Cancer ProgramAnnual Report
PRESIDENT’S MESSAGE
2
At the Statesir Cancer Center at CentraState Medical Center, our ability to fight cancer with advancedtechnology and greater precision is continuously improving – extending the lives of many peoplethroughout our region, and generating hope for many more. Looking back on the past year, we haveembraced this progress on many fronts.
Our radiation therapy technologies are becoming more and more precise, sparing healthysurrounding tissue from damage and ensuring a better quality of life after cancer treatment. We areusing targeted therapies to personalize cancer treatment with medications that are based on a patient’sspecific genetic makeup – often resulting in more effective treatment with fewer side effects. Our clinicaltrials program is studying new ways of treating cancer, such as cryoablation of early-stage breastlesions. In addition, we have enhanced our da Vinci minimally invasive robotic surgical system with thelatest generation da Vinci Xi robot, with high-definition optics optimized for complex, multi-quadrantsurgeries, including cancer surgery.
CentraState pairs these technologies with a skilled multidisciplinary team dedicated to treating our patients with specialized insightand compassion. This includes two new gastrointestinal oncology surgeons who recently joined our team, along with a new dedicatedbreast nurse navigator to ensure comprehensive support from detection to follow-up care for our breast cancer patients.
Because support remains important long after cancer treatment, we have enhanced our survivorship programming and integratedour efforts with referring physicians. Of course, we also place a strong emphasis on community outreach for early detection andcancer prevention initiatives.
Speaking to our expertise and commitment to the highest quality standards, we are proud to have earned and maintained thefollowing third-party accreditations:
• Three-year reaccreditation from the Commission on Cancer (CoC) of the American College of Surgeons, with four commendationsand zero deficiencies
• National Accreditation Program for Breast Centers (NAPBC) of the American College of Surgeons
• College of American Pathologists Laboratory Accreditation Program
• CEO Cancer Gold Standard reaccreditation from the CEO Roundtable on Cancer
• American College of Radiology accreditations in Radiation Oncology, Diagnostic Imaging Center of Excellence (DICOE), BreastImaging Center of Excellence (BICOE), and Low-Dose Rate CT Lung Screening Center of Excellence
As you will see throughout this report, CentraState is committed to continuing our strides in the battle against cancer – and toenabling patients throughout our community to live their lives to the fullest.
Sincerely,
John T. Gribbin, FACHEPresident and CEOCentraState Healthcare System
CANCER PROGRAM AT A GLANCE
3
The Statesir Cancer Center at CentraState Medical CenterAdvancing Community-Based Cancer Care
For more information about the Statesir Cancer Center at CentraState, call 1-855-411-CANCER or visit www.centrastate.com/cancercenter.
OUR MISSIONTo enhance the health and well-being of our communities through the compassionate delivery of quality health care.
CANCER COMMITTEE
4
The Cancer Committee is comprised of an interdisciplinary team of CentraState Medical Center’s Medical and Dental Staff. The goal of the committee isto ensure that CentraState provides a coordinated, multidisciplinary approach to cancer prevention, detection, and treatment, supported by state-of-the-art technology and specially trained staff. The committee is responsible for ensuring compliance with the American College of Surgeons (ACoS) Commissionon Cancer standards and providing the highest and most appropriate standard of care for cancer patients treated at CentraState Medical Center (CSMC).The committee meets quarterly to assess, plan, and implement all cancer-related programs and activities at the hospital. The committee strives tocontinually improve patient survival statistics and patient outcomes so that the quality of life for all cancer patients, and for families dealing with a cancerdiagnosis, is enhanced.
Each year, the Cancer Committee establishes, implements, and monitors clinical programmatic, quality improvement, and community outreach goals toenhance cancer-related care. These goals are accomplished with an emphasis on wellness, education, prevention, survivorship, research, and stringentmonitoring of comprehensive, quality cancer care.
2017 Cancer Committee MembersAsch, Barry MPA, RTTAVP – Cancer Services
Balar, Bhavesh MDMedical Oncologist – Chair, Cancer Committee
Brown, Terri RN, BSN, MEdHealth Awareness Center – Nurse Educator
Buccino, Nicole RN, MSN, CCRNNurse Manager – Ambulatory Services
Craig, Jayne PhD, RNManager – Clinical Research
Crant-Oksa, Aimee MS, RDClinical Nutrition Manager
Dedea, MicheleAmerican Cancer Society
DiMatteo, John MS RPhDirector – Pharmacy
Douglas, Sharon, BCCChaplain/Pastoral Care
Eyd-Adonizio, Janine RNOncology Nurse Navigator
Freeman, Karen CPHRM, CCLAVP Quality/Patient Safety
Joyce, Elana RNNurse Manager, 4 East Oncology
Kelly, Kim RN, MS, NEA-BC, FACHEVice President – Clinical Services
Kharod, Amit MDGeneral Surgeon – Chief of Surgery
Klein Taylor, Jean PTPhysical Therapist
Lorfing, Sharon RN, MSN, APN-CNurse Practitioner – Cancer Services/Nurse Navigator
Mazza, Jean CTRCoC Program Supervisor
Martucci, Mary DOBreast Surgical Oncologist/DirectorBreast Program
Olsen, Melissa MA, CCLSCancer Navigator
Poznanski, Katherine RNPalliative Care Nurse
Pratz, ValerieDirector of Marketing andBusiness Development
Scott, Thomas FACHE, FABCChief Operating Officer
Sharma, Vikrant MDPalliative Care Medical Director
Simon, Paul DOMedical Director – Pathology
Tomkovich, Kenneth MDDiagnostic Interventional Radiologist
Turi-Smith, Deb BA, CSWSupport Service – Social Work
Weber, Gloria RTTChief Therapist, Radiation Therapy
Wortman, MandiDirector of Radiology
Yuhas, Barbara MSN, RN-BC, NE-BCDirector of Nursing – Med/Surg Division
Zapcic, Kathleen RNVNA
2017 ADHOC MembersBessemer, Emily DPT, CLTPhysical Therapist
Bocage, Jean-Philippe MDThoracic Surgery
Dworkin, Jack MD, MBA, FACCVice President/Chief Medical Officer
Dykeman, Maryellen RN, MSN, CCE, TDTSCommunity Wellness Manager
Dymyd, Elaine RN, BSNHealth Awareness Center Program Coordinator
Gribbin, John FACHEPresident/CEO
Keehn, Donna BSN, RNPI Coordinator/PI/Case Management
Mason, Brian PT, DPTClinical Director of Rehabilitative Services
Soffen, Edward MD, FACPRadiation Oncologist
2017 STATESIR CANCER CENTER
ACHIEVEMENTS & ACTIVITIES
5
2017 Cancer CommitteeProgrammatic Goals • Formalize Survivorship Programming
• Recruit GI Specialty Surgeons
- Both Goals Achieved
2017 Cancer Committee Clinical Goals• Update/Revise Reflex Testing for Non-Invasive BreastCancer Patients
• Implement /Demonstrate Improved Quality ThroughDeformable Registration for Radiation Treatment Planning
- Both Goals Achieved
2017 Quality Improvement Projects• Compliance with Evidence-Based Guidelines: Prostatestudy to confirm post-treatment PSA is in compliance withNCCN guidelines
• Lung Resection Study: Per AJCC staging – Focus review onlymph node stations removed vs. the number of lymphnodes removed
• Breast Cancer Study: Study possible changes to improvethe number of days to first treatment for breast cancersurgical patients
• Prostate Cancer Patient Questionnaire evaluating patientexperience and quality of care in radiation oncology
Other Achievements• Installed a PET/CT unit
• Launched an integrated cardio-oncology program forpatients receiving chemotherapy and patients receivingradiation to the chest
Cancer Navigation• Reorganized the cancer navigation team, raising the totalnumber of navigators from 1.2 FTE to 2.2 FTE
• Hired new nurse navigator
• Expanded services with a dedicated breast nurse navigatorand a social worker
Survivorship• Significant increase in Survivorship Care Plan usage, with123 distributed in 2017
• Formalized patient notification of recommendedsurvivorship programs
• Integrated survivorship programming with referringphysicians
• 10th Annual Survivor Day – June
Accreditations• Commission on Cancer (CoC)
• National Accreditation Program for Breast Centers (NAPBC)
• College of American Pathologists (CAP)
• CEO Cancer Gold Standard
• American College of Radiology (ACR) accreditations in:
- Radiation Oncology
- Diagnostic Imaging Center of Excellence (DICOE)
- Breast Imaging Center of Excellence (BICOE)
- Low-Dose Rate CT Lung Screening Center of Excellence
The Karen Olbis RadiationOncology Center• Acquired and implemented state-of-the-art DeformableRegistration software
• Acquired Breath Hold Technology for the treatment ofbreast and other types of thoracic cancers
(continued)
ACHIEVEMENTS & ACTIVITIES
2017 STATESIR CANCER CENTER
6
New Physicians ProvidingCancer Services• Amy Tilara, MD – Gastroenterology
• Jae Lee, MD – Radiation Oncology
• Derrick Christian, MD – GI Surgeon
Research – Clinical Trials• IceSense3 – Cryoablation of Early Stage Breast Lesions - Principle Investigator – K. Tomkovich, MD
• PARTIQoL – Prostate Advanced Radiation TechnologiesInvestigating Quality of Life: Phase III - Site Principle Investigator – E. Soffen, MD
• A Companion Study to PARTIQoL- Site Principle Investigator – E. Soffen, MD
• Ultrasound Characterization of MammographicallySuspicious Calcifications – Retrospective Chart Review- Principle Investigator – K. Tomkovich, MD
• Sun Protection Habits and Attitudes among HealthcareWorkers in a NJ Coastal Hospital- Principle Investigator – J. Craig, PhD
Star and Barry TobiasWomen’s Health Center• VNA Ladies Night Out – February
• CentraState Employees Ladies Night Out – April
• Family Practice Ladies Night Out – May
• Walmart Health Fair – July
• Internal Medicine Health Fair – August
• United Health Care Ladies Night Out – October
• VNA NJCEED Ladies Night Out – October
• CentraState Employees Ladies Night Out – November
Prevention and Community Outreach• Paulette’s C of Blue Race for Colorectal Cancer – May
• Survivor Day – June
• Making Strides Against Breast Cancer – October
• HPV Prevention
- HPV Educational Lecture – October
- School Nurse Workshop – December
• Great American Smoke Out – November
• 80% by 2018 Colon Screening Sponsors
- American Cancer Society (ACS) Relay for Life – June
• Choose Your Cover – Belmar Beach – July
• Support Groups for Breast, Lymphoma, Colorectal, andBladder Cancers Plus Bereavement Support Group
• Day of Beauty and Health – April
• Staff and Foundation Support of Cancer-RelatedOrganizations Including:
- American Cancer Society
- Leukemia Lymphoma Society
- Mary’s Place by the Sea
- Stomp the Monster
- Bladder Cancer Advocacy Network (BCAN)
• 2017 Screenings
- Prostate/Colorectal – January
- Skin/Thyroid – February
- Colorectal Cancer – March
- Oral Cancer – April
- Skin Cancer – May
- Oral Cancer – June
- Skin Cancer – August
- Skin/Thyroid – September
- Prostate/Colorectal – October
- Colorectal Cancer – November
2017 STATESIR CANCER CENTER
MARKETING CAMPAIGN
7
The Statesir Cancer Center at CentraState campaign was based on the tagline“Advancing Community-Based Cancer Care.” The goal of the campaign wasto elevate the image of the cancer center as well as increase preference forcancer services.
CentraState created five different concepts for various mediums to highlightunique cancer offerings in four cancer sites: skin, colorectal, prostate, andlung. The campaign was designed with inherent flexibility so that new servicescould easily be added. Unique selling points were emphasized for each area:
Prostate cancer - CentraState was the first hospital in New Jersey to offera clinical trial for SpaceOAR, a hydrogel that protects organs surrounding theprostate during radiation therapy. A CentraState radiation oncologist wasone of only 10 in the U.S. to be chosen for this trial based on his extensiveexperience in prostate seed implantation. A second ad for prostate cancerpromoted robotic surgery, a less invasive treatment modality for prostatecancer.
Skin cancer - CentraState is one of only a few hospitals in New Jersey to offerbrachytherapy for skin cancer. This non-surgical radiation solution for treatingskin cancer leaves virtually no scars. This is vitally important to patients,particularly when skin cancer affects visible areas such as the face, wherecosmetic concerns are greater.
Colorectal cancer - A CentraState surgeon was the first in Monmouth andOcean counties to perform robotic-assisted colorectal cancer surgery, whichis much less invasive than traditional surgery.
Lung cancer - CentraState lung cancer surgeons have performed more than8,000 video-assisted thoracic surgeries. Their experience, paired with thisinnovative, less invasive procedure, helped to reinforce the skills ofCentraState physicians as well as the available technology.
2016 COMMUNITY OUTREACH PROGRAMS
WITH OUTCOMES
8
The accountability measures were developed by the CoC with the expectation that cancer registries would collect the necessary data to assess and monitorconcordance with the following measures. Extensive assessment and validation of the measures was performed using cancer registry data reported to theNational Cancer Database (NCDB).
The following outcomes for the CentraState Medical Center (CSMC) Statesir Cancer Center represent the 2014 reported performance outcome rates for theBreast Cancer Accountability Measures at the November 8, 2016 Cancer Committee meeting. For the first measure at 98% for radiation treatment followingBreast Conserving Surgery (BCSRT) for all women under age 70, CSMC was reported to be above the national estimated performance rate (shown in green).
The second measure at 100% for chemotherapy (MAC-multi agent chemotherapy) for women under age 70 with American Joint Commission on Cancer (AJCC)Stage T1c N0 M0, or Stage IB – III hormone receptor negative breast cancer, CSMC was reported to be above the national estimated performance rate (shownin green).
The third measure at 92% for Hormone Therapy (HT) American Joint Commission on Cancer (AJCC) Stage T1c N0 M0, or Stage IB – III hormone receptor positivebreast cancer, CSMC was reported to be slightly below the national estimated performance rate (shown in green).
The fourth measure at 100% for radiation therapy for women with mastectomy (MASTRT) for breast cancer with > 4 positive regional lymph nodes; CSMCwas reported to be above the National estimated performance rate (shown in green).
Commission on Cancer (CoC) Standard 4.4Public Reporting of Outcomes for Breast Cancer
Select Measures by the CoC NCDB CP3R ProgramBreast Cancer Accountability Measures:
Radiation is administered within 1 year (365 days) of diagnosis for women under the age of70 receiving breast conserving surgery for breast cancer (Accountability)
Combination chemotherapy is recommended or administered within 4 months (120 days) ofdiagnosis for women under 70 with AJCC T1c No, or Stage IB – III hormone receptornegative breast cancer (Accountability)
Tamoxifen or third generation aromatase inhibitor is recommended or administered within1 year (365 days) of diagnosis for women with AJCC T1c No, or Stage IB – III hormonereceptor positive breast cancer (Accountability)
Radiation therapy is recommended following any mastectomy within 1 year (365 days) ofdiagnosis of breast cancer with > 4 positive regional lymph node (Accountability)
Measure
BCSRT
MAC
HT
MASTRT
CSMC Minus National EstimatedPerformance Difference
5.20
7.50
-0.20
11.80
Public Reporting of Outcomes for Breast Cancer Accountability Measures
98
100
92
100
90
92
94
96
98
100
BCSRT MAC HT MASTRT
NCDB
As an accredited organization of the Commission on Cancer (CoC) as well as the National Accreditation Program forBreast Centers (NAPBC), the breast cancer patients at Statesir Cancer Center can be assured that they are receivingcare that is consistent with nationally recognized standards.
Percentage
LOW-DOSE CT LUNG SCREENING
FROM 2013-2016
9
Smoking and exposure to industrial toxins, such as asbestos, are the leading causes of lung cancer. The best ways to prevent lung cancer are to neversmoke and avoid environmental toxins. The Star and Barry Tobias Health Awareness Center at CentraState Medical Center offers a comprehensive smokingcessation program and other community health and wellness programs aimed at preventing lung cancer.
Early-stage lung cancers are generally asymptomatic. When symptoms do occur, the cancer has usually advanced to a late stage. Symptoms may varydepending on tumor type, location, and size. Typical symptoms include cough, dyspnea, fatigue, wheezing, pain, and weight loss. Over half of individualsdiagnosed with lung cancer die within one year.
From the inception date of the low-dose CT program in 2013 through the end of 2016, the Statesir Cancer Center Cancer Committee reported the followingoutcomes:
611700
600
500
400
300
200
100
Fre
qu
en
cy
Patients Screened
513
98
160
Total Patients Screened
Total Patients with Abnormal Findings
Total Patients with Normal Findings
Total Patients Diagnosed with Cancer
Low-Dose CT Program
PRIMARY CANCER SITES
2014-2016 TOP FIVE
10
0
50
100
150
200
250
Breast Colorectal Lung Prostate Bladder
2014
2015
2016
Frequency
Statistical Summary of Cancer Registry Data
11
Primary Site Table: Newly Diagnosed and/or Treated Cases Seen at CentraState — 2016
Sex Status Stage Distribution - Analytic Cases Only
Primary Site Total (%) M F Alive Exp Stg 0 Stg I Stg II Stg III Stg IV Unknown
ORAL CAVITY & PHARYNX 11 (1.1%) 10 1 10 1 0 0 1 1 2 3Tongue 1 (0.1%) 1 0 1 0 0 0 0 0 0 0Salivary Glands 3 (0.3%) 3 0 3 0 0 0 1 1 0 1Floor of Mouth 1 (0.1%) 1 0 1 0 0 0 0 0 0 1Gum & Other Mouth 3 (0.3%) 2 1 2 1 0 0 0 0 1 0Tonsil 2 (0.2%) 2 0 2 0 0 0 0 0 1 0Oropharynx 1 (0.1%) 1 0 1 0 0 0 0 0 0 1
DIGESTIVE SYSTEM 191 (18.4%) 99 92 148 43 5 31 33 17 37 17Esophagus 10 (1.0%) 9 1 8 2 0 2 2 0 2 0Stomach 15 (1.4%) 11 4 12 3 1 5 0 0 3 3Small Intestine 3 (0.3%) 1 2 2 1 0 1 0 0 0 1Colon Excluding Rectum 62 (5.9%) 28 34 53 9 3 10 8 11 9 6Cecum 13 7 6 13 0 0 3 3 4 1 1Appendix 4 2 2 4 0 0 1 0 0 0 0Ascending Colon 6 2 4 6 0 0 0 2 3 0 1Hepatic Flexure 6 4 2 5 1 0 2 0 1 1 2Transverse Colon 6 1 5 3 3 0 1 3 0 1 1Splenic Flexure 1 0 1 1 0 0 0 0 0 1 0Descending Colon 2 1 1 1 1 1 0 0 1 0 0Sigmoid Colon 10 4 6 10 0 1 3 0 1 2 1Large Intestine, NOS 14 7 7 10 4 1 0 0 1 3 0Rectum & Rectosigmoid 24 (2.3%) 15 9 23 1 0 3 6 3 4 2Rectosigmoid Junction 10 7 3 10 0 0 2 2 3 1 0Rectum 14 8 6 13 1 0 1 4 0 3 2Anus, Anal Canal, & Anorectum 3 (0.3%) 1 2 3 0 0 2 0 0 0 0Liver & Intrahepatic Bile Duct 10 (1.0%) 5 5 7 3 0 0 1 1 1 3Liver 7 4 3 5 2 0 0 1 1 0 3Intrahepatic Bile Duct 3 1 2 2 1 0 0 0 0 1 0Gallbladder 8 (0.8%) 1 7 5 3 1 0 1 2 3 1Other Biliary 3 (0.3%) 2 1 2 1 0 2 0 0 0 0Pancreas 48 (4.6%) 23 25 30 18 0 4 15 0 15 1Retroperitoneum 1 (0.1%) 0 1 1 0 0 1 0 0 0 0Peritoneum, Omentum. & Mesentery 1 (0.1%) 1 0 1 0 0 1 0 0 0 0Other Digestive Organs 3 (0.3%) 2 1 1 2 0 0 0 0 0 0
RESPIRATORY SYSTEM 156 (14.9%) 69 87 105 51 0 35 7 24 50 4Larynx 7 (0.7%) 7 0 7 0 0 3 0 2 1 0Lung & Bronchus 149 (14.2%) 62 87 98 51 0 32 7 22 49 4
BONES & JOINTS 3 (0.3%) 2 1 2 1 0 1 0 0 0 0Bones & Joints 3 (0.3%) 2 1 2 1 0 1 0 0 0 0
SOFT TISSUE 5 (0.5%) 2 3 5 0 0 0 2 1 0 0
SKIN EXCLUDING BASAL 21 (2.0%) 14 7 17 4 3 5 2 1 2 1& SQUAMOUSMelanoma - Skin 16 (1.5%) 10 6 13 3 3 3 1 0 2 1Other Non-Epithelial Skin 5 (0.5%) 4 1 4 1 0 2 1 1 0 0
BREAST 230 (22.0%) 4 226 219 11 37 82 50 13 7 8
Statistical Summary of Cancer Registry Data
Primary Site Table: Newly Diagnosed and/or Treated Cases Seen at CentraState — 2016
Sex Status Stage Distribution - Analytic Cases Only
Primary Site Total (%) M F Alive Exp Stg 0 Stg I Stg II Stg III Stg IV Unknown
FEMALE GENITAL SYSTEM 43 (4.1%) 0 43 37 6 0 13 1 5 4 5Cervix Uteri 3 (0.3%) 0 3 3 0 0 0 0 0 1 2Corpus & Uterus, NOS 34 (3.2%) 0 34 30 4 0 13 1 5 1 3Corpus Uteri 32 0 32 29 3 0 13 1 5 1 3Uterus, NOS 2 0 2 1 1 0 0 0 0 0 0Ovary 5 (0.5%) 0 5 3 2 0 0 0 0 2 0Vulva 1 (0.1%) 0 1 1 0 0 0 0 0 0 0
MALE GENITAL SYSTEM 138 (13.3%) 138 0 131 7 0 16 56 24 10 0Prostate 130 (12.5%) 130 0 123 7 0 11 56 22 10 0Testis 7 (0.7%) 7 0 7 0 0 5 0 2 0 0Penis 1 (0.1%) 1 0 1 0 0 0 0 0 0 0
URINARY SYSTEM 109 (10.4%) 78 31 99 10 37 32 7 9 6 3Urinary Bladder 65 (6.2%) 54 11 60 5 35 11 4 1 2 3Kidney & Renal Pelvis 40 (3.8%) 21 19 36 4 1 21 2 7 4 0Ureter 2 (0.2%) 1 1 2 0 0 0 1 1 0 0Other Urinary Organs 2 (0.2%) 2 0 1 1 1 0 0 0 0 0
BRAIN & OTHER 16 (1.5%) 8 8 13 3 0 0 0 0 0 0NERVOUS SYSTEMBrain 12 (1.1%) 8 4 9 3 0 0 0 0 0 0Cranial Nerves Other 4 (0.4%) 0 4 4 0 0 0 0 0 0 0Nervous System
ENDOCRINE SYSTEM 25 (2.4%) 8 17 25 0 0 8 1 5 1 2Thyroid 24 (2.3%) 8 16 24 0 0 8 1 5 1 2Other Endocrine including Thymus 1 (0.1%) 0 1 1 0 0 0 0 0 0 0
LYMPHOMA 47 (4.5%) 22 25 41 6 0 14 7 12 2 0Hodgkin Lymphoma 7 (0.7%) 4 3 6 1 0 3 2 1 0 0Non-Hodgkin Lymphoma 40 (3.8%) 18 22 35 5 0 11 5 11 2 0NHL - Nodal 34 15 19 30 4 0 7 4 11 2 0NHL - Extranodal 6 3 3 5 1 0 4 1 0 0 0
MYELOMA 13 (1.2%) 6 7 9 4 0 0 0 0 0 0
LEUKEMIA 17 (1.6%) 10 7 14 3 0 0 0 0 0 0Lymphocytic Leukemia 11 (1.0%) 8 3 10 1 0 0 0 0 0 0Acute Lymphocytic Leukemia 1 0 1 1 0 0 0 0 0 0 0Chronic Lymphocytic Leukemia 10 8 2 9 1 0 0 0 0 0 0Myeloid & Monocytic Leukemia 4 (0.4%) 2 2 2 2 0 0 0 0 0 0Acute Myeloid Leukemia 2 1 1 0 2 0 0 0 0 0 0Chronic Myeloid Leukemia 2 1 1 2 0 0 0 0 0 0 0Other Leukemia 2 (0.2%) 0 2 2 0 0 0 0 0 0 0
MESOTHELIOMA 2 (0.2%) 2 0 1 1 0 1 0 0 0 0
MISCELLANEOUS 17 (1.6%) 7 10 12 5 0 0 0 0 0 0
Total 1,044 (100%) 479 565 888 156 82 238 167 112 121 84
Exclusions: Not Male and Not Female
12
CANCER REGISTRY STATISTICS
13
n (0) Initial diagnosis at CSMC and first course of treatment atanother facility
n (1) Diagnosis at CSMC, and all or part of first course oftreatment at CSMC
n (2) Diagnosis at another facility, and all or part of first course oftreatment at CSMC
2016 Analytic Cases at CentraState (CSMC)
13.75%
2.08%
82.50%
1.66%
2016 Non-Analytic Cases at CentraState (CSMC)
Analytic cases: Patients who were diagnosed and/or received treatment for their newly diagnosed cancer at CSMC
Non-analytic cases: Patients who were seen for the first time at CSMC only for consultation, diagnostic work-up, transient care,management of recurrent disease, or treatment of non-malignant conditions (with active cancer diagnosis)
n Initial diagnosis and first course of treatment elsewhere, CSMCparticipated in diagnostic work-up
n Initial diagnosis and first course of treatment elsewhere, CSMCparticipated in providing transit care
n Initial diagnosis and first course of treatment elsewhere, CSMCparticipated in management of recurrent disease
n Patient treated at physician’s office, only received diagnosticwork-up
18.78%
65.92%
15.29%
CSMC 2014 - 2016 Breast Cancer
by Age at Diagnosis
0
10
20
30
40
0-39 40-49 50-59 60-69 70-79 80-89 90+
2014
2015
2016
Percentage
Age
CSMC 2014 - 2016 Breast Cancer
by Class of Case
0
10
20
30
40
50
60
Class 00 (Diagnosed atCSMC, all first course oftreatment elsewhere)
Class 10-14 (Diagnosed atCSMC and all or part offirst course of treatment
at CSMC)
Class 20-22 (Diagnosedelsewhere and all or part of
first course of treatmentat CSMC)
2014
2015
2016
Perc
en
tag
e
14
15
CSMC 2014 - 2016 Lung Cancer
0
5
10
15
20
25
30
35
40
45
0-39
Age
40-49 50-59 60-69 70-79 80-89 90+
Perc
en
tag
e 2014
2015
2016
by Age at Diagnosis
CSMC 2014 - 2016 Breast vs NCDB
by Stage at Diagnosis
0
5
10
15
20
25
30
35
40
45
50
0 I II III IV Unknown
Perc
en
tag
e
2014 2015 2016 NCDB 2014Stage
16
CSMC 2014 - 2016 Lung Cancer
0
10
20
30
40
50
60
70
80
Perc
en
tag
e
Class 00 (Diagnosed atCSMC, all first course oftreatment elsewhere)
Class 10-14 (Diagnosedat CSMC and all or part
of first course oftreatment at CSMC)
Class 20-22 (Diagnosedelsewhere and all or part
of first course oftreatment at CSMC)
2014
2015
2016
by Class of Case
CSMC 2014 - 2016 Lung Cancer vs NCDB
0
5
10
15
20
25
30
35
40
45
I II III IV Unknown
Perc
en
tag
e
2014 2015 2016 NCDB 2014Stage
by Stage at Diagnosis
CSMC 2014 - 2016 Colorectal Cancer
17
0
5
10
15
20
25
30
35
0-39 40-49 50-59 60-69 70-79 80-89 90+
Perc
en
tag
e
2014
2015
2016
Age
by Age at Diagnosis
CSMC 2014 - 2016 Colorectal Cancer
0
10
20
30
40
50
60
70
80
Perc
en
tag
e
Class 00 (Diagnosed atCSMC, all first course oftreatment elsewhere)
Class 10-14 (Diagnosed atCSMC and all or part offirst course of treatment
at CSMC)
Class 20-22 (Diagnosedelsewhere and all or part of
first course of treatmentat CSMC)
2014
2015
2016
by Class of Case
18
CSMC 2014 - 2016 Colorectal vs NCDB
by Stage at Diagnosis
0
5
10
15
20
25
30
35
0 I II III IV Unknown
Perc
en
tag
e 2014
2015
2016
NCDB 2014
Stage
CSMC 2014 - 2016 Prostate Cancer
0
5
10
15
20
25
30
35
40
0-39 40-49 50-59 60-69 70-79 80-89 90+
Perc
en
tag
e
2014
2015
2016
Age
by Age at Diagnosis
19
CSMC 2014 - 2016 Prostate Cancer
0
10
20
30
40
50
60
70
80
90
Perc
en
tag
e
Class 00 (Diagnosed atCSMC, all first course oftreatment elsewhere)
Class 10-14 (Diagnosedat CSMC and all or part
of first course oftreatment at CSMC)
Class 20-22 (Diagnosedelsewhere and all or
part of first course oftreatment at CSMC)
2014
2015
2016
by Class of Case
CSMC 2014 - 2016 Prostate Cancer vs NCDB
0
10
20
30
40
50
60
70
I II III IV Unknown
Perc
en
tag
e
2014
2015
2016
NCDB 2014
Stage
by Stage at Diagnosis
The full circle of health and wellness dedicated to excellence
901 West Main Street • Freehold, NJ 07728(732) 294-7080 • www.centrastate.com
TM
For more information about the Statesir Cancer Center at CentraState,
call 1-855-411-CANCER or visit www.centrastate.com/cancercenter.
